Fig. 4: Venetoclax mitigates MM-MSCs support of adjacent MM cells’ survival and sensitizes them to anti-MM drug Bortezomib.
From: Myeloma mesenchymal stem cells’ bioenergetics afford a novel selective therapeutic target
ND and MM MSCs (n ≥ 3) were pre-treated with Venetoclax (Ven) (SRC inhibitor, 0.5 µM; 24 h) then co-cultured with RPMI-8226 or MM.1S MM cell lines (MM cells) in the presence of Ven for 48 h or added with Bortezomib (BTZ)(anti-MM drug, 5 nM; last) for the last 24 h of 72 h of co-culture. Untreated MM cells alone or in co-culture served as controls. A Ven’s effect on co-cultured (with ND/MM-MSCs, 72 h) MM cells’ Viability (Presto-Blue). B, C Ven ± BTZ effect on co-cultured (with MM-MSCs, 72 h) MM cells’ Viability (Presto-Blue) and total cell count (Trypan-Blue). Cell counts and viability were normalized to untreated MM cells cultured alone. Results are expressed as percentage (Mean ± SE, n ≥ 3). Asterisks depicted statistical significance *p < 0.05; **p < 0.005.
